

Systematic Review of the Approach towards Vaccination and Available Treatment for COVID-19 with Special Reference to India

Gware P^{1*}, Rajput P²

¹Department of Biotechnology, Anand Engineering College, Agra, India

²Manager, 99 Digital Solutions, Ghaziabad, India

ABSTRACT

An intense respiratory ailment, brought about by a novel coronavirus (SARS-CoV-2, recently known as 2019-nCoV), the coronavirus sickness 2019 (COVID-19) has spread all through China and got overall consideration. On 30 January 2020, World Health Organisation (WHO) formally proclaimed the COVID-19 pestilence as a general wellbeing crisis of global concern. The rise of SARS-CoV-2, since the serious intense respiratory disorder coronavirus (SARS-CoV) in 2002 and Middle East respiratory disorder coronavirus (MERS-CoV) in 2012, denoted the third presentation of a profoundly pathogenic and enormous scope plague coronavirus into the human populace in the twenty-first century. Starting at 1 March 2020, a sum of 87,137 affirmed cases universally, 79,968 affirmed in China and 7169 outside of China, with 2977 passings (3.4%) had been accounted for by WHO. In the interim, a few autonomous research bunches have recognized that SARS-CoV-2 has a place with β -coronavirus, with exceptionally indistinguishable genome to bat coronavirus, highlighting bat as the characteristic host. The epic coronavirus utilizes a similar receptor, angiotensin-changing over compound 2 (ACE2) as that for SARS-CoV, and for the most part spreads through the respiratory tract. Critically, progressively proof demonstrated supported human-to-human transmission, alongside many sent out cases over the globe. The clinical side effects of COVID-19 patients incorporate fever, hack, weariness and a little populace of patients showed up gastrointestinal contamination side effects. The old and individuals with basic ailments are helpless to contamination and inclined to genuine results, which might be related with intense respiratory trouble disorder (ARDS) and cytokine storm. At present, there are scarcely any particular antiviral methodologies, however a few intense applicants of antivirals and repurposed drugs are under examination.

Keywords: COVID-19; SARS-CoV; WHO; Human-to-human transmission

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a form of viral pneumonia with an unprecedented outbreak in December 2019 in Wuhan, China, caused by the extreme acute respiratory coronavirus syndrome 2 (SARS-CoV-2). The appearance of SARS-CoV-2 was identified as the third introduction of a highly pathogenic coronavirus into the human population following the extreme acute respiratory coronavirus syndrome.

CASE REPORT

Molecular structure

Coronaviruses are infections whose genome structure is ideal known among all RNA infections. 66% of RNA they have encodes viral polymerase (RdRp), RNA amalgamation materials, what's more, two huge nonstructural polyproteins that are not included in have reaction regulation (ORF1a-ORF1b). The other 33% of the genome encodes four basic proteins spike (S), envelope (E), layer (M) and nucleocapsid (N), and the other aide

Correspondence to: Pramod Gware, Department of Biotechnology, Anand Engineering College, Agra, India, Tel: +05613-272025; E-mail: pramod.gware@sgei.org

Received: May 13, 2020; **Accepted:** May 27, 2020; **Published:** June 03, 2020

Citation: Gware P, Rajput P (2020) Systematic Review of the Approach towards Vaccination and Available Treatment for COVID-19 with Special Reference to India. *Virology & Mycology*. 9:188. DOI: 10.35248/2161-0517.20.09.188.

Copyright: © 2020 Gware P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

proteins. Although the length of the CoV genome shows high inconstancy for ORF1a/ORF1b and four auxiliary proteins, it is for the most part related with the number and size of adornment proteins. The initial phase in infection disease is the communication of delicate human cells with Spike Protein. After entering the cell, the viral RNA show itself in the cytoplasm. Genomic RNA is typified and polyadenylated, and encodes different basic and non-auxiliary polypeptide qualities. These polyproteins are part by proteases that display chymotrypsin-like activity [1-3]. The subsequent complex drives (-) RNA creation through both replication and translation. During replication, full-length (-) RNA duplicates of the genome are delivered and utilized as a format for full-length (+) RNA genomes [1,2]. During translation, a subset of 7-9 sub-genomic RNAs, including those encoding every single auxiliary protein, are delivered by intermittent interpretation.

Viral nucleocapsids are joined from genomic RNA and R protein in the cytoplasm and afterward are grown into the lumen of the endoplasmic reticulum. Virions are at that point discharged from the contaminated cell through exocytosis. The discharged infections can contaminate kidney cells, liver cells, digestive organs, T lymphocytes, just as the lower respiratory tract, where they structure the primary side effects and signs [3]. Remarkably, CDT lymphocytes were seen as lower than 200 cells/mm³ in three patients with SARS-CoV contamination. MERS-CoV can influence human dendritic cells and macrophages in-vitro. T lymphocytes are additionally an objective for the pathogen because of the trademark CD26 rosettes. This infection can make the antiviral T- cell reaction sporadic due to the incitement of T-cell apoptosis, therefore causing a breakdown of the safe system [4,5].

The virus is a positive-strand RNA virus which has a strong bat coronavirus homology. The assault will trigger less and less hemoglobins capable of carrying oxygen and carbon dioxide. Because of the inability to regularly exchange carbon dioxide and oxygen, the lung cells have extremely severe poisoning and inflammatory, which ultimately results in ground-glass pulmonary images. According to the confirmation review of these results, chloroquine may prevent porphyrin-forming orf1ab, ORF3a, and ORF10 attacking the heme and inhibiting to some degree the binding of ORF8 and surface glycoproteins to porphyrins, effectively alleviating the symptoms of respiratory distress. Favipiravir may inhibit porphyrin binding to the envelope protein and ORF7a protein, preventing the virus from entering host cells, and catching free porphyrins. Researchers studying how coronaviruses such as COVID-19 infect human cells have shown that the SARS-CoV-2 spike (S) glycoprotein binds to the angiotensin-converting enzyme 2 (ACE2) in the cell membrane protein to enter human cells. COVID-19 was shown to bind to ACE2 via the surface of the S protein. During infection, the S protein is cleaved into subunits, S1 and S2 (Figure 1).




Figure 1: SARS- CoV 2 Structure. Contributed by Rohan Bir Singh, MD; Made with Biorender.com from: Features, Evaluation and Treatment Coronavirus (COVID-19), Treasure Island (FL): Stat Pearls Publishing; 2020 Jan.

Recombinant SARS-CoV-2 protein

All coronaviruses, including the coronavirus (SARS-CoV-2, COVID-19), which was first identified in Wuhan City, China in December 2019, encode the nucleocapsid protein (N-protein) and the spike protein (S-protein). Both recombinant forms of these proteins are now available at Ray Biotech to advance research into infectious diseases.

Nucleocapsid protein (N-Protein)

Nucleocapsid protein (N-protein) is a structural protein that binds to the RNA genome of the coronavirus and thus produces a shell (or capsid) around the enclosed nucleic acid. N-protein also 1) interacts with the viral membrane protein during viral assembly, 2) assists in the synthesis and folding of RNA, 3) plays a role in the budding virus, and 4) influences the responses of host cells, including the cell cycle and translation.

Spike protein

The spike protein (S-protein) performs two primary tasks that help in host infection: 1) mediate the connection between the virus and host cell surface receptors; and 2) promote viral entry into the host cell by assisting in the fusion of viral and host cell membranes.

ACE2

ACE2 is an endogenous membrane protein allowing for an infection with COVID-19. Throughout infection, ACE2's extracellular peptidase domain binds to the spike protein receptor binding domain, which is a protein on the SARS-CoV-2 surface.

In 2003, the SARS-CoV infection pulled the world's yield somewhere near \$50 billion. The early estimation for the cost to the worldwide economy because of the episode of COVID-19 is about \$360 billion [6]. This is since China's GDP shares were roughly 17% all around starting at 2019, which was around multiple times higher than in 2003, and the affirmed tainted cases (at the hour of doing the financial estimation, i.e., toward the start of February 2020) are multiple occasions bigger than the aggregate of SARS. Given that the quantity of contaminated cases (109,343 affirmed cases) is at present around multiple times bigger than SARS cases [7], and that the loss of life due to COVID-19 has outperformed that of the SARS pestilence, the financial effect of COVID-19 may be a lot bigger than \$360 billion. Besides, so as to win the fight against this flare-up, data on the epidemiological attributes, for example, the recognizable proof of the creature repositories and the hazard factor of the malady, is additionally basic [8]. The middle of the road have conveying the illness is critical to recognize for the present scourge, yet in addition to dispose of a future episode. Together with the all previously mentioned factors, the race for an inoculation against COVID-19 is similarly fundamental. Despite the fact that at this phase there is no enrolled treatment or antibody for COVID-19, Zhang has as of late referenced some potential intercessions, for example, wholesome mediations (Vitamin A, B, C, D, E, and other follow minerals, for example, zinc and iron). Because of the high level of identity in the succession (up to 82% of the genome structure) between SARS-CoV-2 and the SARS-CoV infection, immuno-enhancers and other explicit treatment that have been applied for SARS could likewise be considered [9] to use for the treatment of SARS-CoV-2.

PROPOSED TREATMENT OF COVID-19

Current treatments

Given the absence of successful antiviral treatment against COVID-19, current medicines essentially centered around symptomatic what's more, respiratory help as per the Diagnosis what's more, Treatment of Pneumonia Caused by COVID-19 (refreshed to rendition 6) gave by National Health Commission of the People's Republic of China [10]. Almost all patients acknowledged oxygen treatment, and WHO prescribed extracorporeal film oxygenation (ECMO) to patients with obstinate hypoxemia [11]. Salvage treatment with healing plasma and immunoglobulin G12 are conveyed to some basic cases as indicated by their conditions.

Antiviral medications

In view of the experience of battling the scourge SARSCoV furthermore, MERS-CoV already, we may become familiar with certain exercises for some treatment methodologies against coronavirus [12,13]. Antiviral medications and foundational corticosteroid treatment usually utilized in clinical practice already, including neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, and so forth), ganciclovir, acyclovir, and ribavirin, as well as methylprednisolone [20,14] for flu infection, are invalid for COVID-19 and not prescribed. Chloroquine is a repurposed medicate with extraordinary potential to treat

COVID-19. Chloroquine has been utilized to treat intestinal sickness for a long time, [15] with an instrument that isn't well comprehended against some popular diseases. A few potential systems are explored: Chloroquine can hinder pH-subordinate strides of the replication of a few infections, [16] with a powerful impact on SARS-CoV disease what's more, spread [17]. Besides, chloroquine has immunomodulatory impacts, smothering the creation/discharge of TNF- α and IL-6. It likewise fills in as a novel class of autophagy inhibitor, [18] which may meddle with viral disease and replication. A few examinations have discovered that chloroquine meddled with the glycosylation of cell receptors of SARS-CoV17 and worked at both passage and at post-section phases of the COVID-19 disease in Vero E6 cells [19,20].

Transmission

In December 2019, numerous pneumonia cases that were grouped in Wuhan city were accounted for and looks for the source have demonstrated Huanan Seafood Market as the birthplace. The primary instance of the COVID-19 plague was found with unexplained pneumonia on December 12, 2019, and 27 viral pneumonia cases with seven being extreme, were formally declared on December 31, 2019 [21-23]. Etiologic examinations have been acted in patients who applied to the clinic because of comparative viral pneumonia discoveries. The regular history of high-chance creature contact in the clinical narratives of these patients has reinforced the probability of a contamination transmitted from creatures to people [21,24]. On January 22, 2020, novel CoV has been pronounced to be started from wild bats and had a place with Group 2 of beta-coronavirus that contains Severe Acute Respiratory Disorder Associated Coronavirus (SARS-CoV). In spite of the fact that COVID-19 and SARS-CoV have a place with a similar beta coronavirus subgroup, likeness at genome level is just 70%, and the novel gathering has been found to show hereditary contrasts from SARS-CoV.24 Like the SARS plague, this flare-up has happened throughout the Spring Festival in China, which is the most popular customary celebration in China, during which about 3 billion individuals travel countrywide. These conditions caused positive conditions for the transmission of this profoundly infectious illness and extreme challenges in counteraction and control of the pandemic, while the time of the celebration was between January 10 and February 18 out of 2020. Thus, there was a quick increment in COVID-19 cases between January 10-22, 2020 Wuhan, the focal point of the plague with 10 million populace, is additionally a significant focus in the spring celebration transportation arrange. The assessed number of explorers during the 2020 spring celebration has risen 1.7 folds when contrasted and the number voyaged in 2003 and came to 3.11 billion from 1.82 billion. This enormous scope travel traffic has additionally made ideal conditions for the spread of this hard to-control disease [25].

COVID-19 IN INDIA

On 11 March 2020, WHO pronounced Novel Coronavirus Disease (COVID-19) episode as a pandemic and emphasized the call for nations to take prompt activities and scale up reaction to treat, recognize and decrease transmission to spare individuals

lives. On 24 March 2020, the Prime Minister declared a 21-day across the nation lockdown: "So as to secure the nation, and every one of its residents, from 12 PM today, a total boycott is being forced on individuals from venturing out of their homes.

Starting at 7 May 2020 (8:00 PM), as indicated by the Ministry of Health and Family Welfare (MoHFW), a sum of 35902 active cases of COVID-19 cases, (counting 66 remote nationals) have been accounted for in 30 states/association regions. These incorporate 15266 who have been relieved/released, 1 who has moved and 1783 passings. Emergency clinic separation of every single affirmed case, following and home isolate of the contacts is continuous

WHO Country Office for India has been working intimately with MoHFW on readiness and reaction measures for COVID-19, including observation and contact following, lab finding, hazard correspondences and network commitment, emergency clinic readiness, contamination counteraction and control, and execution of regulation arrangement. India is at a vital point in its battle against COVID-19. The nation has reacted with direness and assurance as reflected in the Prime Minister's striking and conclusive leadership. The government has additionally forcefully ventured up the reaction measures - find, seclude, test, treat and follow. WHO is supporting the administration's undertaking to additionally reinforce and increase reconnaissance and construct limit of the wellbeing framework

Legislature of India is finding a way to guarantee that we are arranged well to confront the test and danger presented by the developing pandemic of COVID 19-the Corona Virus. With dynamic help of the individuals of India, the situation is far better than other countries. The most significant factor in forestalling the spread of the Virus locally is to engage the residents with the correct data and avoiding potential risk according to the warnings being given by Ministry of Health and Family Welfare.

PROPOSED TREATMENT OF COVID-19

Hydroxychloroquine and chloroquine are oral professionally prescribed medications that have been utilized for treatment of intestinal sickness and certain incendiary conditions. Hydroxychloroquine and chloroquine are under scrutiny in clinical preliminaries for pre- introduction or post-presentation prophylaxis of SARS-CoV-2 disease, and treatment of patients with mellow, moderate, and serious COVID-19. The antiviral movements of chloroquine and HCQ have been recognized in the *in vitro* investigations and the development of a wide range of infections have been repressed in the cell culture line by both the operators, counting the SARS coronavirus. Mice consider have additionally exhibited action of these operators against human coronavirus OC43, enterovirus EV-A71, Zika infection and flu A H5N1. The job of chloroquine against Human Immunodeficiency Virus was uncertain [26].

Plasma therapy

A few nations, including India, are genuinely taking a gander at plasma treatment as a potential treatment for Covid-19, the

illness brought about by the novel coronavirus. Plasma treatment utilizes blood gave by recuperated patients to present antibodies in those under treatment. The gaining strength plasma treatment targets utilizing antibodies from the blood of a recouped Covid-19 patient to treat those fundamentally influenced by the infection. The treatment can likewise used to vaccinate those at a high danger of getting the infection. This current treatment's idea is straightforward and depends on the reason that the blood of a patient who has recuperated from Covid-19 contains antibodies with the particular capacity of battling novel coronavirus. The hypothesis is that the recouped patient's antibodies, once ingested into someone under treatment, will start targeting and battling the novel coronavirus in the subsequent patient. The healing plasma treatment is similar to uninvolved inoculation as, as indicated by scientists, it is a preventive measure and not a treatment for the Covid-19 sickness.

DISCUSSION AND CONCLUSION

All in all, the event and advancement of SARS-CoV-2 rely upon the association between the infection and the person's resistant framework. Viral components incorporate infection type, change, viral burden, viral titer, and reasonability of the infection *in vitro*. The person's resistant framework factors incorporate hereditary qualities, (for example, HLA qualities), age, sex, wholesome status, neuroendocrine-insusceptible guideline, and physical status. These components all add to whether an individual is contaminated with the infection, the length and seriousness of the sickness, and the reinfection. In the beginning periods of the pestilence, precise finding helps control the spread of the sickness. It is basic to grow new, sheltered, exact, quick and straightforward new innovations for distinguishing SARS-CoV-2. Obviously, doctors will deliberately mediate in the two variables to cause them to form into a bearing gainful to human wellbeing, which can enable patients to recuperate as quickly as time permits. Be that as it may, it must not be viewed as that clinical mediation can accomplish a 100% corrective impact.

REFERENCES

1. Luk HK, Li X, Fung J, Lau SK, Woo PC. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. *Infct Genet Evol.* 2019;71:c21-30.
2. Neuman BW. Coronavirinae in viral zone. SIB Swiss Institute of Bioinformatics. 2020.
3. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidylpeptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP. *Crit Rev Clin Lab Sci.* 2003;40(3):209-294.
4. Chu H, Zhou J, Wong BH, Li C, Cheng ZS, Lin X, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. *Virol.* 2014;454(455):197-205.
5. Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis. *J Infect Dis.* 2014;209(9):1331-1242.

6. Economic vulnerabilities to the Coronavirus: Top countries at risk. 2020.
7. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet*. 2020;395(10223):470-473.
8. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(10):270-273.
9. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. *J. Med Virol*. 2020;92(5):479-490.
10. National Health Commission of the People's Republic of China. Diagnosis and treatment of pneumonia caused by 2019-nCoV. 2020.
11. World Health Organization (WHO). Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020.
12. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis*. 2020;20(4):398-400.
13. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug discovery and therapeutic options. *Nat Rev Drug Discov*. 2016;15(5):327-347.
14. Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 novel Coronavirus. *Chin J Tuberc Respir Dis*. 2020;43(8):e002.
15. Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. *Int J Parasitol Drugs Drug Resist*. 2018;8(3):459-464.
16. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases?. *Lancet Infect Dis*. 2003;3(11):722-727.
17. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology*. 2005;2(1):69.
18. Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. *Neurosurg Focus*. 2015;38(3):e12.
19. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020;30(7):269-271.
20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-1069.
21. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology*. 2018;23(8):130-137.
22. Imperial College London. Report 2: estimating the potential total number of novel coronavirus cases in Wuhan City, China. 2020.
23. World Health Organization (WHO), 2019-nCoV Situation Report. 2020.
24. Gralinski L, Menachery V. Return of the Coronavirus: 2019-nCoV. *Viruses*. 2020;12(7):135.
25. Chen Z, Zhang W, Lu Y. From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of early epidemic and prediction of future trends: *Cell Press*. 2020.
26. Chauhan A, Tikoo A. The enigma of the clandestine association between chloroquine and HIV-1 infection. *HIV Med*. 2015;16:e90.